Australia markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
41.48-4.40 (-9.59%)
At close: 04:00PM EST
41.62 +0.14 (+0.34%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close45.88
Open44.69
Bid41.62 x 1000
Ask41.75 x 800
Day's range41.33 - 44.76
52-week range11.64 - 146.16
Volume2,307,061
Avg. volume4,820,606
Market cap1.66B
Beta (5Y monthly)0.42
PE ratio (TTM)N/A
EPS (TTM)-0.56
Earnings date21 Mar 2022 - 25 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target est159.25
  • Zacks

    Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs

    Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

  • Motley Fool

    Where Will Cassava Sciences Be in 1 Year?

    First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.

  • Motley Fool

    3 Healthcare Stocks That Could Rocket Higher in 2022

    A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.